Blood group determinates incidence for pancreatic cancer in Germany

Frontiers in Physiology

Volumn 4 MAY, Issue , 2013, Pages

  Pelzer, U ^a   Klein, F ^a   Bahra, M ^a   Sinn, M ^a   Dorken B ^a   Neuhaus, P ^a   Meyer, O ^a   Riess, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ABO blood group system; Determination; Genome; Pancreatic cancer; Risk factor

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD GROUP A; BLOOD GROUP AB; BLOOD GROUP ABO SYSTEM; BLOOD GROUP B; BLOOD GROUP O; BLOOD GROUP RH; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS RESECTION;

EID: 84883753506     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00118     Document Type: Article

References (23)

1. Adler, G., Seufferlein, T., Bischoff, S. C., Brambs, H.-J., Feuerbach, S., Grabenbauer, G., et al. (2007). S3-Guidelines "Exocrine pancreatic cancer" 2007. Z Gastroenterol. 45, 487-523.
2. Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., et al. (2009). Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 10, 943-949.
3. Amundadottir, L., Kraft, P., Stolzenberg-Solomon, R. Z., Fuchs, C. S., Petersen, G. M., Arslan, A. A., et al. (2009). Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet. 41, 986-990.
4. Ben, Q., Wang, K., Yuan, Y., and Li, Z. (2011). Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int. J. Cancer 128, 1179-1186.
5. Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825.
6. Engin, H., Bilir, C., Üstün, H., and Gökmen, A. (2012). ABO blood group and risk of pancreatic cancer in a Turkish population in Western Blacksea region. Asian Pac. J. Cancer Prev. 13, 131-133.
7. Gong, Y., Yang, Y.-S., Zhang, X.-M., Su, M., Wang, J., Han, J.-D., et al. (2012). ABO blood type, diabetes and risk of gastrointestinal cancer in northern China. World J. Gastroenterol. 18, 563-569.
8. Greer, J. B., LaRusch, J., Brand, R. E., O'Connell, M. R., Yadav, D., and Whitcomb, D. C. (2011). ABO blood group and chronic pancreatitis risk in the NAPS2 cohort. Pancreas 40, 1188-1194.
9. Greer, J.-B., Yazer, M.-H., Raval, J.-S., Barmada, M.-M., Brand, R.-E., and Whitcomb, D.-C. (2010). Significant association between ABO blood group and pancreatic cancer. World J. Gastroenterol. 16, 5588-5591.
10. He, M., Wu, C., Xu, J., Guo, H., Yang, H., Zhang, X., et al. (2013). A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and a fetoprotein and their associations with cancer risk. Gut. doi: 10.1136/gutjnl-2012-303434. [Epub ahead of print].
11. Iodice, S., Maisonneuve, P., Botteri, E., Sandri, M. T., and Lowenfels, A. B. (2010). ABO blood group and cancer. Eur. J. Cancer. 46, 3345-3350.
12. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300.
13. Khalili, H., Wolpin, B. M., Huang, E. S., Giovannucci, E. L., Kraft, P., Fuchs, C. S., et al. (2011). ABO blood group and risk of colorectal cancer. Cancer Epidemiol. Biomark. Prev. 20, 1017-1020.
14. Maisonneuve, P., Iodice, S., Löhr, J.-M., and Lowenfels, A. B. (2009). Re: ABO blood group and the risk of pancreatic cancer. J. Natl. Cancer Inst. 101, 1156; author reply 1156-1157.
15. Nakao, M., Matsuo, K., Hosono, S., Ogata, S., Ito, H., Watanabe, M., et al. (2011). ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci. 102, 1076-1080.
16. Pelzer, U. (2008). First-line chemotherapy in advanced pancreatic cancer. Recent Res. Cancer Res. 177, 57-60.
17. Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., et al. (2011). Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur. J. Cancer. 47, 1676-1681.
18. Pelzer, U., Bahra, M., Sinn, M., Dörken, B., Neuhaus, P., Meyer, O., et al. (2012). "AB0 Blood group and risk of pancreatic cancer in a German single center cohort," in Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Oncology (Stuttgart), A: 684.
19. Riess, H., Pelzer, U., Hilbig, A., Stieler, J., Opitz, B., Scholten, T., et al. (2008). Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer. 8:361. doi: 10.1186/1471-2407-8-361
20. Risch, H. A. (2012). Pancreatic cancer: helicobacter pylori colonization, N-nitrosamine exposures, and ABO blood group. Mol. Carcinog. 51, 109-118.
21. Wolpin, B. M., Kraft, P., Xu, M., Steplowski, E., Olsson, M. L., Arslan, A. A., et al. (2010). Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol. Biomark. Prev. 19, 3140-3149.
22. Woo, S. M., Joo, J., Lee, W. J., Park, S.-J., Han, S.-S., Kim, T. H., et al. (2013). Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study. J. Korean Med. Sci. 28, 247-251.
23. Yeo, T. P., and Lowenfels, A. B. (2012). Demographics and epidemiology of pancreatic cancer. Cancer. J. 18, 477-484.